Evidence map›Paper›PMID 25375154›Full record

Trial reportPloS one2014

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.

Lisanne L Krens, Lieke H J Simkens, Jara M Baas, Els R Koomen, Hans Gelderblom, Cornelis J A Punt, Henk-Jan Guchelaar

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Statin as a therapeutic agent in gastroenterological cancer.World journal of gastrointestinal oncology · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Bioactive lipids in cancer stem cells.World journal of stem cells · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lisanne L KrensDept. of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Lieke H J SimkensDept. of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Jara M BaasDept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Els R KoomenDept. of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Hans GelderblomDept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Cornelis J A PuntDept. of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Henk-Jan GuchelaarDept. of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLAcademic Medical Center · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastatic colorectal cancer patients (mCRC) treated with cetuximab. Treatment data were obtained from patients who were treated with capecitabine, oxaliplatin bevacizumab ± cetuximab in the phase III CAIRO2 study. A total of 529 patients were included in this study, of whom 78 patients were on statin therapy. In patients with a KRAS wild type tumor (n = 321) the median PFS was 10.3 vs. 11.4 months for non-users compared to statin users and in patients with a KRAS mutant tumor (n = 208) this was 7.6 vs. 6.2 months, respectively. The hazard ratio (HR) for PFS for statin users was 1.12 (95% confidence interval 0.78-1.61) and was not influenced by treatment arm, KRAS mutation status or the KRAS*statin interaction. Statin use adjusted for covariates was not associated with increased PFS (HR = 1.01, 95% confidence interval 0.71-1.54). In patients with a KRAS wild type tumor the median OS for non-users compared to statin users was 22.4 vs. 19.8 months and in the KRAS mutant tumor group the OS was 18.1 vs. 14.5 months. OS was significantly shorter in statin users versus non-users (HR = 1.54; 95% confidence interval 1.06-2.22). However, statin use, adjusted for covariates was not associated with increased OS (HR = 1.41, 95% confidence interval 0.95-2.10). In conclusion, the use of statins at time of diagnosis was not associated with an improved PFS in KRAS mutant mCRC patients treated with chemotherapy and bevacizumab plus cetuximab.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCetuximabColorectal NeoplasmsDisease-Free SurvivalFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMutationOrganoplatinum CompoundsOxaliplatinBevacizumabCetuximabHydroxymethylglutaryl-CoA Reductase InhibitorsKRAS protein, humanOrganoplatinum CompoundsOxaliplatinProto-Oncogene Proteins p21(ras)

Identifiers

PMID25375154
PMCPMC4223044
OpenAlexW2049594890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.